Assessment of Health Economics in Alzheimer’s Disease (AHEAD)Treatment with Galantamine in Sweden

被引：0
|
作者：
Frances B. Garfield
Denis Getsios
J. Jaime Caro
Anders Wimo
Bengt Winblad
机构：
[1] Caro Research Institute,Division of General Internal Medicine, Royal Victoria Hospital
[2] Caro Research,Division of Geriatric Medicine
[3] McGill University,undefined
[4] Neurotec,undefined
[5] Karolinska Institutet,undefined
来源：
PharmacoEconomics | 2002年 / 20卷
关键词：
Nursing Home; Rivastigmine; Tacrine; Galantamine; Nursing Home Care;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background: Like other developed countries with aging populations, Sweden is expecting large increases in the prevalence of Alzheimer’s disease and corresponding escalations in the cost of care for patients with this disease. Galantamine, a new acetylcholinesterase inhibitor and nicotinic modulator, has proved effective in managing patients with Alzheimer’s disease in clinical trials.
引用
收藏
页码：629 / 637
页数：8
相关论文
共 50 条
  • [1] Assessment of health economics in Alzheimer's disease (AHEAD) - Treatment with galantamine in Sweden
    Garfield, FB
    Getsios, D
    Caro, JJ
    Wimo, A
    Winblad, B
    PHARMACOECONOMICS, 2002, 20 (09) : 629 - 637
  • [2] Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK
    Ward, A
    Caro, JJ
    Getsios, D
    Ishak, K
    O'Brien, J
    Bullock, R
    INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2003, 18 (08) : 740 - 747
  • [3] Assessment of health economics in Alzheimer's disease (AHEAD) - Galantamine treatment in Canada
    Getsios, D
    Caro, JJ
    Caro, G
    Ishak, K
    NEUROLOGY, 2001, 57 (06) : 972 - 978
  • [4] Galantamine in the treatment of Alzheimer's disease
    Latalova, K. L.
    Pidrman, V.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2006, 16 : S476 - S476
  • [5] Assessment of health economics in Alzheimer's disease (AHEAD) based on need for full-time care
    Caro, JJ
    Getsios, D
    Migliaccio-Walle, K
    Raggio, G
    Ward, A
    NEUROLOGY, 2001, 57 (06) : 964 - 971
  • [6] Galantamine hydrobromide in a treatment of Alzheimer's disease
    Nikolova, G
    Yancheva, S
    Raychev, I
    Dobreva, D
    Traykov, L
    NEUROBIOLOGY OF AGING, 2002, 23 (01) : S96 - S96
  • [7] Galantamine vs Donepezil in the Treatment of Alzheimer’s Disease
    Barry Goldlist
    Michael Gordon
    Gary Naglie
    Drugs & Aging, 2003, 20 : 1139 - 1140
  • [8] Current Guidelines Treatment of Alzheimer's Disease with Galantamine
    Eitorf, Katrin Wolf
    NERVENHEILKUNDE, 2010, 29 (11) : 790 - 790
  • [9] Galantamine (Reminyl) - New treatment for Alzheimer's disease
    不详
    AMERICAN JOURNAL OF NURSING, 2001, 101 (06) : 24AAAA - 24AAAA
  • [10] Galantamine treatment in outpatients with mild Alzheimer's disease
    Richarz, U.
    Gaudig, M.
    Rettig, K.
    Schauble, B.
    ACTA NEUROLOGICA SCANDINAVICA, 2014, 129 (06): : 382 - 392
12345